I read with interest the excellent article on sudden cardiac death risk stratification with electrocardiographic (ECG) indices by Dr. Gimeno-Blanes and his colleagues in the recent issue of Frontiers in Physiology (Gimeno-Blanes et al., ). The article is unique in that it included computational processing, technology transfer, and scientific evidence, critical considerations in the long and challenging path from bench to bedside. The parameters discussed, namely heart rate variability, heart rate turbulence, and microvolt T-wave alternans (TWA), are well-considered as they are the most extensively studied contemporary ECG-based risk stratification parameters.
In this commentary, I would like to register some additional considerations with respect to time-domain analysis of microvolt TWA using the Modified Moving Average (MMA) method. We have studied this parameter in our laboratory for more than two decades. The MMA methodology has run the complete gambit from development through clearance by the United States FDA and a recent positive coverage decision by Center for Medicare and Medicaid Services (https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=275). As the authors pointed out, it differs from the spectral method and while there are commonalities, there are critical differences in the approach and in the clinical evidence supporting the two methods. The MMA method employs the noise-rejection principle of recursive averaging. The algorithm continuously streams odd and even beats into separate bins and creates averaged complexes for each bin. These complexes are then superimposed, and the maximum difference between the odd and even complexes at any point within the JT segment is identified for every 15 s and reported as the TWA value. The highest TWA levels within the entire 24-h period are recorded for each subject and used for analysis of risk for sudden cardiac death or cardiovascular mortality. The established TWA cut-point of 47 μV indicates a positive TWA test. Inspection of the TWA template permits verification of the waveform and provides opportunities for insights into the pathophysiology, as distinct patterns are associated with differing disease states. Samples of the rhythm strip and QRS-aligned template are provided (Figure 1; Verrier et al., ).
Figure 1
The experience with the MMA method includes ~1800 patients studied with ambulatory ECG monitoring (Verrier and Malik,
A critical factor is that the TWA testing by both the Spectral and MMA methods needs to be performed on chronic medications, especially beta-adrenergic blockers, as recommended by 11 expert authors of the TWA consensus guideline (Verrier et al.,
It can be argued that because TWA is predictive in patient on medications, it is capable of predicting the effects of medications. This principle may be applicable to the > 12,000 patients in whom TWA has been measured who were receiving antiarrhythmic therapy, as they were drawn from cohorts with diverse forms of coronary artery disease including myocardial ischemia and heart failure. The potential of TWA to guide medical therapy as well as exercise rehabilitation has been recently reviewed (Verrier and Malik,
The authors made some major points that apply not only to TWA testing but to other ECG-based parameters, especially the need to obtain more longitudinal information. The basic physiology and pathophysiology of myocardial substrate and autonomic influences are dynamic, with day-to-day variations and changes in disease state. A prime example is the period following acute myocardial infarction, as considerable remodeling occurs in the ensuing 90 days. For this reason, it has been recommended that risk stratification for long-term prediction be performed only at 10 to 14 weeks after the event. However, it can also be argued that the immediate followup period should not be ignored, particularly in patients with depressed ejection fraction, who are at high risk of dying suddenly in this early period. New possibilities are evolving with advances in telemonitoring, in which ECG patches and smartphone based technologies can be applied (Fung et al.,
While the question can be debated about whether or not quantitative TWA analysis with the MMA method is in prime time, there is considerable evidence that it deserves a position on stage.
Statements
Author contributions
Dr. RLV wrote the submitted commentary on a review by Gimeno-Blanes and colleagues.
Conflict of interest
RLV is co-inventor of the Modified Moving Average method for T-wave alternans analysis, with patent assigned to Georgetown University (Washington, DC) and Beth Israel Deaconess Medical Center (Boston, MA) and licensed to GE Healthcare, Inc. (Milwaukee, WI).
References
1
FungE.JarvelinM. R.DoshiR. N.ShinbaneJ. S.CarlsonS. K.GrazetteL. P.et al. (2015). Electrocardiographic patch devices and contemporary wireless cardiac monitoring. Front. Physiol.6:149. 10.3389/fphys.2015.00149
2
Gimeno-BlanesF. J.Blanco-VelascoM.Barquero-PerezO.Garcia-AlberolaA.Rojo-AlvarezJ. L. (2016). Sudden cardiac risk stratification with electrocardiographic indices-a review on computational processing, technology transfer, and scientific evidence. Front. Physiol.7:82. 10.3389/fphys.2016.00082
3
VerrierR. L.KlingenhebenT.MalikM.El-SherifN.ExnerD.HohnloserS.et al. (2011). Microvolt T-wave alternans: physiologic basis, methods of measurement, and clinical utility. Consensus guideline by the International Society for Holter and Noninvasive Electrocardiology. J. Am. Coll. Cardiol.44, 1309–1324. 10.1016/j.jacc.2011.06.029
4
VerrierR. L.MalikM. (2015). Quantitative T-wave alternans analysis for guiding medical therapy: an underexploited opportunity. Trends Cardiovasc. Med.25, 201–213. 10.1016/j.tcm.2014.10.006
Summary
Keywords
T-wave alternans, sudden cardiac death, ventricular arrhythmias, telemedicine, ischemic heart disease, antiarrhythmic drugs
Citation
Verrier RL (2016) Commentary: Sudden Cardiac Risk Stratification with Electrocardiographic Indices - A Review on Computational Processing, Technology Transfer, and Scientific Evidence. Front. Physiol. 7:267. doi: 10.3389/fphys.2016.00267
Received
02 May 2016
Accepted
15 June 2016
Published
05 July 2016
Volume
7 - 2016
Edited by
Ruben Coronel, Academic Medical Center, Netherlands
Reviewed by
Jose Luis Rojo-Alvarez, Rey Juan Carlos University, Spain
Updates

Check for updates
Copyright
© 2016 Verrier.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Richard L. Verrier rverrier@bidmc.harvard.edu
This article was submitted to Cardiac Electrophysiology, a section of the journal Frontiers in Physiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.